Clinical Trial Update: VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating VX15/2503 with or without ipilimumab and/or nivolumab in patients with resectable stage IIIB–D cutaneous melanoma; study curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• VX15/2503
• Yervoy (ipilimumab)

Snippet

Sponsor: Emory University | Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING